Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral lenalidomide to standard induction therapy in AML and RAEB ≥ 66 years and very poor risk AML ≥ 18 years. A study in the frame of the masterprotocol of parallel randomized phase II studies in elderly AML

Next Previous
Trial Profile

A randomized phase II multicenter study with a safety run-in to assess the tolerability and efficacy of the addition of oral lenalidomide to standard induction therapy in AML and RAEB ≥ 66 years and very poor risk AML ≥ 18 years. A study in the frame of the masterprotocol of parallel randomized phase II studies in elderly AML

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 May 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenalidomide (Primary) ; Cytarabine; Daunorubicin
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Acronyms HOVON-103-AML-Lenalidomide

Most Recent Events

  • 01 May 2021 Results of translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort (n=40), published in the Annals of Hematology.
  • 03 Mar 2012 Planned number of patients changed from 200 to 240 as reported by European Clinical Trials Database.
  • 03 Mar 2012 Planned end date changed from 15 Sep 2012 to 13 Oct 2012 as reported by European Clinical Trials Database.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top